Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome.
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Maralixibat (Primary)
- Indications Alagille syndrome; Intrahepatic cholestasis
- Focus Adverse reactions
- Acronyms Maralixibat Infant Safety Evaluation (RISE).; RISE
- Sponsors Mirum Pharmaceuticals
Most Recent Events
- 26 Aug 2024 Planned number of patients changed from 12 to 27.
- 14 Mar 2024 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
- 11 Feb 2024 This trial has been Completed in Belgium, According to European Clinical Trials Database record.